Company intelligence / Profile preview

Wuhan Binhui Biopharmaceutical Co., Ltd.

Ownership: Private
Development stage: Phase 2

Overview

Binhui Bio’s lead asset is an oncolytic herpes simplex virus type II expressing GM-CSF (“OH2 injection”, also called BS001), which has received five INDs and one orphan drug designation from the NMPA/FDA since 2018. It is the first HSV2-derived OV to enter clinical trials globally. Clinical trials have enrolled over 400 subjects across more than twenty research centers in China for various solid tumor indications. The company also develops bispecific oHSV-based agents targeting PD-L1/CD3, nucleic acid/mRNA vaccines, protein therapeutics, and cell therapies.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Oncolytic viruses (OV)Nucleic acid drugs (including mRNA vaccines)Protein drugs/antibodiesCell therapies
Industry: Biotech

Drug pipeline

7 assets

OH2

6 more assets in the full pipeline.

Beyond the preview

Go deeper on Wuhan Binhui Biopharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Binhui Biopharmaceutical Co., Ltd..